Profil

Sabbe Mare

GIGA Immunobiology - Cellular and Molecular Immunology

Département des sciences cliniques > GIGA

Département des sciences cliniques

See author's contact details
ORCID
0009-0005-2410-8993
Main Referenced Co-authors
Louis, Renaud  (14)
Schleich, Florence  (14)
Guissard, Françoise  (7)
Paulus, Virginie  (7)
Moermans, Catherine  (5)
Main Referenced Keywords
Antibodies, Monoclonal, Humanized (5); Asthma (5); Humans (5); Anti-Asthmatic Agents (4); Asthma/drug therapy (4);
Main Referenced Disciplines
Cardiovascular & respiratory systems (11)
General & internal medicine (3)

Publications (total 14)

The most downloaded
250 downloads
Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64. https://hdl.handle.net/2268/313409

The most cited

3 citations (Scopus®)

Sabbe, M., Schleich, F., Janssens, P., & Louis, R. (31 January 2024). When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. Journal of Medical Case Reports, 18 (1), 63. doi:10.1186/s13256-023-04255-8 https://hdl.handle.net/2268/331151

Most significant publications selected by the Author

Sabbe, M., Schleich, F., & Louis, R. (2025). Biologics alter the relationship between FeNO and sputum eosinophils in severe T2 high asthmatics. ERJ Open Research, 00783-2024. doi:10.1183/23120541.00783-2024
Peer Reviewed verified by ORBi

Louis, F., Sabbe, M., Schleich, F., Philippe, G., & Louis, R. (December 2024). L’étude clinique du mois. L’étude PROMISE : une confirmation de l’efficacité du benralizumab en vie réelle chez les patients asthmatiques sévères éosinophiliques. Revue Médicale de Liège, 79 (12), 807 - 811.
Editorial Reviewed verified by ORBi

Zahraei, H. N., Schleich, F., Louis, G., Gerday, S., SABBE, M., Bougard, N., GUISSARD, F., PAULUS, V., Henket, M., Pétré, B., Donneau, A.-F., & Louis, R. (2024). Evidence for two clusters among non-eosinophilic asthmatics. Annals of Allergy, Asthma and Immunology. doi:10.1016/j.anai.2024.03.012
Peer Reviewed verified by ORBi

Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64.
Editorial Reviewed verified by ORBi


Contact ORBi